Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+6.97%
+1.74%
-3.08%
-1.12%
MLYS
Mineralys Therapeutics
$42.62
Login to see Mineralys Therapeutics (MLYS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Risk Analysis
Earnings are forecast to decrease
Chart
$38.78 (+9.90%)
$14.32 (+197.63%)
$15.84 (+169.07%)
$13.38 (+218.54%)
MLYS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
MLYS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
MLYS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MLYS Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayMLYS Earnings
The TTM reflects 12-month period, providing review of MLYS financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is MLYS current stock price?
What are MLYS stock strengths?
What risks are associated with MLYS stock?
When is MLYS next earnings report?
What is MLYS market cap and volume?
What is MLYS's current Stock IQ?
Should I buy MLYS stock right now?
Is MLYS a Strong Buy right now?
What does a 'Strong Buy' rating mean for MLYS?
What does a 'Strong Sell' rating mean for MLYS?
What factors influence MLYS's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+6.97%
+1.74%
-3.08%
-1.12%
MLYS
Mineralys Therapeutics
Current Price
$42.62
Stock Insights
Risk Analysis
Earnings are forecast to decrease
Login to unlock Mineralys Therapeutics (MLYS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$38.78 (+9.90%)
$14.32 (+197.63%)
$15.84 (+169.07%)
$13.38 (+218.54%)
MLYS Analysts Opinion
MLYS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
MLYS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MLYS Street view is bullish and have positive views on the near-term outlook
MLYS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
Average key support and resistance price levels.
Login to displayMLYS Earnings
The TTM data reflects the most recent 12-month period, providing overview of MLYS financial performance.
MLYS Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
MLYS Latest Analysis
Mineralys Therapeutics CEO Congleton sells $644k in MLYS stock.
Wed Oct 15, 2025
Rodman Mineralys Therapeutics CMO sells $445k in MLYS stock.
Wed Oct 15, 2025
Mineralys Therapeutics CFO sells $451983 in MLYS stock.
Wed Oct 15, 2025
Mineralys Therapeutics Inc. (MLYS) Shows Positive Phase 3 HTN Results Blood Pressure Drops in High-Risk Groups. We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Mineralys Therapeutics Inc. is one of them. Mineralys Therapeutics Inc. (NASDAQ:MLYS) a clinical-stage biopharmaceutical company focuses on developing therapies for diseases caused by dysregulated aldosterone including hypertension chronic kidney disease (CKD) and obstructive sleep apnea. Its lead
Tue Sep 30, 2025
Mineralys Therapeutics Inc. (MLYS) is a Great Momentum Stock: Should You Buy?. Does Mineralys Therapeutics Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Lets find out.
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MLYS Stock trends
MLYS Stock performance
MLYS Stock analysis
MLYS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders